Dräger seeks federal government support amid PFAS ban debate as industry reliance on 'forever chemicals' intensifies
Executive summary: Dräger issued a public appeal to the German federal government for guidance and support regarding the upcoming PFAS ban, as reported by Handelsblatt on August 8, 2026. The PFAS ban threatens to disrupt key industrial sectors reliant on these chemicals, particularly in healthcare and safety equipment, where Dräger is a major player, potentially triggering costly redesigns and supply chain adjustments.
Who is involved: Dräger AG, the German federal government (Bundesregierung), environmental regulators, and industrial users of PFAS in medical and safety technology sectors.
Likely next: The Bundesregierung is expected to release further guidance on transition periods or exemptions for essential uses, while industry lobbies push for extended timelines or substitution support programs.
Dräger’s public call for the German federal government to clarify its position on the forthcoming PFAS ban highlights a growing clash between environmental policy and industrial necessity. The company, which supplies critical components for medical devices and safety equipment, argues that suitable substitutes for per‑ and polyfluoroalkyl substances are still scarce in these high‑performance applications. This stance echoes wider unease among manufacturers who fear that a rapid or poorly defined restriction could disrupt supply chains, raise compliance costs, and force costly redesigns of products that rely on PFAS for durability, chemical resistance, or barrier properties. The appeal matters because any ambiguity in the ban’s scope or timeline could delay investment decisions and hinder the scaling of alternative materials. If the Bundesregierung provides clear guidance, possibly coupled with transitional exemptions or funding for research, firms like Dräger may better manage the shift toward PFAS‑free solutions while maintaining product safety and performance. Conversely, prolonged uncertainty could prompt companies to stockpile existing inventories or seek work‑arounds, potentially inflating short‑term costs. In the near term, the government’s response will likely shape how quickly the industry can adapt and whether the ban proceeds as planned or undergoes adjustments to accommodate essential sectors.
Timeline
- — Umweltpolitik: Dräger hofft beim PFAS-Verbot auf die Bundesregierung (Handelsblatt)
- — KfW-Gesetz: Darf die Bundesregierung den Gewinn der Förderbank abschöpfen? (Handelsblatt)
- — Druck auf Bundesregierung: Gründer und Manager legen dringenden Appell für Reformen vor (Handelsblatt)
Analysis — what this means
Likely next events
- Bundesregierung to publish draft PFAS regulation with transition rules by Q4 2026
- Dräger to announce PFAS-free prototype timeline for anesthesia devices by end of 2026
- EU to review PFAS restriction dossiers under REACH in early 2027
Sectors affected
- Medical technology
- Safety and protective equipment
- Semiconductor manufacturing
- Chemical industrial supplies
Regulatory implications
- EU-wide PFAS restriction under REACH may enforce ban on non-essential uses by 2028
- Germany may seek derogations for medical and industrial safety applications under Article 64 of REACH
- Dräger may need to substitute PFAS in sealing and lubrication components to maintain market access
Historical parallels
- Similar to the phase-out of PCBs in the 1980s under the Stockholm Convention, where industrial adaptation took over a decade
- Parallels with the CFC ban under the Montreal Protocol, which drove innovation in refrigeration and propellants
- Analogous to the EU’s restriction on mercury in measuring devices, prompting redesign in medical thermometers and sphygmomanometers
Key entities
Sources
Open the full interactive case file on Beyond →